On October 16, 2025, Cellectis will host an in-person Investors R&D Day in New York City, at the 1700 Broadway Club, from 8:30 to 10:30 a.m. ET.
WHY ATTEND: Join us for an in-person update with Cellectis leadership, distinguished KOLs, and AstraZeneca.
Agenda highlights:
- Full Phase 1 clinical data for lasme-cel (UCART22) in r/r B-ALL
- Phase 2 trial design and registrational strategy for lasme-cel
- Live panel and Q&A with B-ALL KOLs
- Update on our strategic partnership with AstraZeneca
Attendance is by invitation only.
To register: cellectis@astrpartners.com
October 16, 2025
New York City